CAD with chest X-ray to screen for lung cancer may reveal abnormalities, but more study is required.
Computer-aided detection (CAD) with standard chest radiography screening for lung cancer among high-risk patients identified additional actionable lung nodules not found by standard X-ray, according to a study published this month in PLOS One. However, the authors warned that the number of nodules found was too small to draw definitive conclusions and further study is needed.
Researchers from the Cleveland Clinic undertook a randomized screening trial and enrolled 1,424 patients, aged 40 to 75, who had 10 or more pack-years of smoking history and/or who had an additional risk for developing lung cancer. The subjects were randomized to receive either a posterior-anterior view chest radiograph or a sham X-ray.
Researchers evaluated 1,423 patients, 701 of whom received a CAD chest radiograph. Both the plain and CAD images were interpreted by two experienced readers blinded to each other’s findings. Actionable nodules were reported and additional evaluation was tracked. The primary outcome was the rate of developing symptomatic advanced stage lung cancer.
Data were available at six-month follow up for 80.8 percent of the patients, at 12 months for 66.5 percent, at 18 months for 38.5 percent and at 24 months or longer for 1.8 percent.
The researchers found that the readers spotted 22 nodules (11 each reader) among the unaided X-rays and 29 actionable nodules among the CAD X-rays, 11 of which were deemed not to require follow-up.
Of the nodules detected by CAD X-ray and not on standard X-ray, the researchers noted that the nodules were more likely to be smaller and less solid than the ones noted on the standard X-ray.
According to the authors, “the cumulative incidence of symptomatic advanced lung cancer was 0.42 cases per 100 person-years in the control arm; there were no events in the screening arm.”
They concluded that more research is necessary to determine if CAD chest radiography can have a future role as a lung cancer screening tool.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.